RxDoctor Payments Data

Deborah Miller, MD

Otolaryngology · Webster, TXNPI 1144219700

Payments from drug & device makers

$7,312in general payments, 2019–2025

Across 210 payments — averaging $34.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$1K
  • Aerin Medical Inc.$1K
  • AbbVie$1K
  • Merz North America, Inc.$1K
  • Galderma Laboratories, L.p.$375
  • Optinose US, Inc.$314
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$89012%
  • Food & beverage$6,42288%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,312 in reported general payments places this provider in the 80th percentile of 729 otolaryngology providers in Texas.

See all otolaryngology providers in Texas

Medicare billing

Part B allowed, 2024
$154,633
Medicare patients
266
Services billed
3,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl76$2,937
Epinephrine13$2,895
Tobramycin-DexamethasoneTobramycin/Dexamethasone45$2,643
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth18$1,996
Famotidine58$843
Np ThyroidThyroid,pork17$803
Fluocinolone Acetonide Oil16$707
Montelukast Sodium20$505
Omeprazole15$362
Cefdinir16$292
Mupirocin27$227
Fluticasone Propionate11$201
Methylprednisolone16$112
Alprazolam19$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$85$2,89513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 otolaryngology providers in Texas.

Other otolaryngology in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →